Aave’s decentralized finance (DeFi) network is recording all-time highs in usage and liquidity, yet the token’s price remains well below historic peaks. According to expert Ignas, Aave is generating over $3 million in weekly revenue while total deposits have surged past $56 billion. Despite these robust figures, AAVE’s price is still 66% below its 2021 […]Aave’s decentralized finance (DeFi) network is recording all-time highs in usage and liquidity, yet the token’s price remains well below historic peaks. According to expert Ignas, Aave is generating over $3 million in weekly revenue while total deposits have surged past $56 billion. Despite these robust figures, AAVE’s price is still 66% below its 2021 […]

Aave Hits $56 Billion in Deposits While AAVE Price Tests $210 Support

2025/11/11 13:30
3 min read
Aave
  • Aave hits record activity metrics with $3M weekly revenue and $56B in total deposits, despite price lagging.
  • Short-term price rebound observed near $210–$222, testing support for potential recovery.
  • Medium-term resistance around $280–$360 crucial for confirming an uptrend.

Aave’s decentralized finance (DeFi) network is recording all-time highs in usage and liquidity, yet the token’s price remains well below historic peaks.

According to expert Ignas, Aave is generating over $3 million in weekly revenue while total deposits have surged past $56 billion. Despite these robust figures, AAVE’s price is still 66% below its 2021 all-time high and 39% down since last December.

The contrast highlights how the lack of a broad altcoin rally has affected even established protocols. Lower borrowing demand and reduced airdrop farming activity have brought borrowing costs down, contributing to a healthier, more sustainable market environment.

Currently, AAVE is trading at $221.37, up 4.11% in the past 24 hours, with a market cap of $3.38 billion and a 24-hour trading volume of $470.44 million, showing a 72% increase in activity. These metrics indicate renewed interest in the protocol even as the token remains in a lower price range.

Weekly Bounce Signals Early Buying Support

Technically speaking, it is clear on the chart for AAVE on a weekly timeframe that one market formation is a bounce for this token off a recent low of about $210. The formation is a small-bodied green candle following multiple red candles.

Areas to keep an eye on in support regions are $205-$210, which is now positioned close to the lower boundary of the Bollinger Bands, and then a strong historical support zone is $150-$160.

The primary long-term supports lie in the regions of $80-$120, which have been tested recently in every deep market correction. Areas to watch in the resistance regions are $280 and then $355-$360.

The Bollinger Bands show slight contraction in the lower direction, with AAVE testing the lower boundary, which is indicative of it being over-sold.

The RSI is 43.88, which is below 50 and thus it is slightly bearish but not overtly so. The MACD is slightly negative at -5.59 and is showing signs of levelling out.

Also Read: Aave Struggles Below $200 as Bulls Aim for $243.50 Recovery Target

AAVE Consolidation Range Holds Between $160 and $355

AAVE is still ranging between $160 and $355. Short-term trends seem slightly positive, with a probable swing-back to $250-$280 if $205 levels are maintained.

Medium-term market trends are neutral to negative until the $280 resistance is cleared. Long-term accumulation levels around $160-$170 indicate a probable swing-back to $350+ if market sentiments change.

Also Read: Aave Technical Setup Signals Possible Short-Term Rebound Toward $225

Market Opportunity
AaveToken Logo
AaveToken Price(AAVE)
$109.25
$109.25$109.25
-2.98%
USD
AaveToken (AAVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26